Human CXCL13/BLC/BCA-1 PE-conjugated Antibody
Human CXCL13/BLC/BCA-1 PE-conjugated Antibody Summary
Val23-Arg94
Accession # O43927
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of CXCL13/BLC/BCA‑1 in Human Immature Dendritic Cells by Flow Cytometry. Human immature dendritic cells (CD14+ PBMC cultured with 20 ng/mL rhIL-4 and 50 ng/mL rhGM-CSF for 7 days) were stained with Mouse Anti-Human CXCL13/BLC/BCA-1 PE-conjugated Monoclonal Antibody (Catalog # IC801P, filled histogram) or isotype control antibody (Catalog # IC002P, open histogram). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog # FC005). View our protocol for Staining Intracellular Molecules.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: CXCL13/BLC/BCA-1
CXCL13, also known as B-lymphocyte chemoattractant (BLC), is a CXC chemokine that is constitutively expressed in secondary lymphoid organs. BCA-1 cDNA encodes a protein of 109 amino acid residues with a leader sequence of 22 residues. Mature human BCA-1 shares 64% amino acid sequence similarity with the mouse protein and 23-34% amino acid sequence identity with other known CXC chemokines. Recombinant or chemically synthesized BCA-1 is a potent chemoattractant for B lymphocytes but not T lymphocytes, monocytes or neutrophils. BLR1, a G protein-coupled receptor originally isolated from Burkitt’s lymphoma cells, has now been shown to be the specific receptor for BCA-1. Among cells of the hematopoietic lineages, the expression of BLR1, now designated CXCR5, is restricted to B lymphocytes and a subpopulation of T helper memory cells. Mice lacking BLR1 have been shown to lack inguinal lymph nodes. These mice were also found to have impaired development of Peyer’s patches and defective formation of primary follicles and germinal centers in the spleen as a result of the inability of B lymphocytes to migrate into B cell areas.
- Gunn, M.D. et al. (1998) Nature, 391:799.
- Legler, D.F. et al. (1998) J. Exp. Med. 187:655.
- Forster, R. et al. (1996) Cell 87:1037.
Product Datasheets
Citation for Human CXCL13/BLC/BCA-1 PE-conjugated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Human Sox4 facilitates the development of CXCL13-producing helper T cells in inflammatory environments
Authors: H Yoshitomi, S Kobayashi, A Miyagawa-H, A Okahata, K Doi, K Nishitani, K Murata, H Ito, T Tsuruyama, H Haga, S Matsuda, J Toguchida
Nat Commun, 2018-09-19;9(1):3762.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human CXCL13/BLC/BCA-1 PE-conjugated Antibody
Average Rating: 4 (Based on 1 Review)
Have you used Human CXCL13/BLC/BCA-1 PE-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
